Currently, treatment modalities of advanced HCC are limited, which include programmed cell death protein 1 (PD-1) inhibitor plus vascular endothelial growth factor inhibitor and several tyrosine kinase inhibitors (TKIs) (such as sorafenib, lenvatinib, and donafenib) (8, 9). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.